DLBCL

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

The FDA granted both a regenerative medicine advanced therapy and fast track designation to C-CAR039 for relapsed or refractory diffuse large B-cell lymphoma.

During a live virtual event, Ann LaCasce, MD, MMSc, discusses third-line treatment options for diffuse large B-cell lymphoma when considering eligibility for chimeric antigen receptor T-cell therapy.

In an interview with Targeted Oncology, Mark Roschewski, MD, discussed precision medicine in diffuse large B-cell lymphoma and using acalabrutinib in a pre-chemotherapy window to better understand its potential benefit.

For a 41-year-old female patient with diffuse large B-cell lymphoma, multiple treatment options exists. Elizabeth A. Brem, MD discussed the options during an interview with Targeted Oncology.

During a live virtual event, Paolo Caimi, MD, discussed the barriers to using loncastuximab tesirine for diffuse large B-cell lymphoma preceding chimeric antigen receptor T-cell therapy.

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies.

During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.

Early study results indicate that YTB323 may be effective and safe for the treatment of patients with diffuse large B-cell lymphoma.

Polatuzumab vedotin-piiq added to the R-CHOP regimen elicited a high progession-free survival rate in patients with newly-diagnosed diffuse large B-cell lymphoma.

An RMAT designation granted to FT516 is supported by data from a phase 1 trial of FT516 in patients with diffuse large B-cell lymphoma.

The efficacy and safety of naratuximab emtansine plus rituximab appear impressive for patients with B-cell non-Hodgkin lymphomas who are ineligible for stem cell transplant or chimeric antigen receptor T-cell therapy.

The use of ibrutinib plus loncastuximab tesirine induced encouraging anti-tumor activity and a manageable safety profile in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma, according to results from an interim analysis of the LOTIS-3 trial.

During a live virtual event, Paolo Caimi, MD, discussed third-line treatment of a patient with diffuse large B-cell lymphoma and navigating obstacles to treatment.

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.

Following 6 well-tolerated cycles of R-CHOP, a 75-year-old patient with diffuse large B-cell lymphoma showed complete remission on a PET scan. But 1 year later, the disease relapsed.

During a live virtual event, Beth A. Christian, MD, discussed real-world challenges of providing timely access to CAR-T cell therapy for patients with diffuse large B-cell lymphoma.

During a live virtual event, Beth A. Christian, MD, discussed approaches to third-line treatment of transplant-ineligible DLBCL and when to consider CAR T-cell therapy.

Jason Westin, MD, discusses unmet clinical needs in diffuse large B-cell lymphoma landscape. 

While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.

Eleven months after completing therapy for diffuse large B-cell lymphoma, a 43-year-old patients reported fever, night sweats, and back pain, and a palpable lymph node was discovered in her left groin.

Justin Kline, MD, discusses what makes loncastuximab tesirine-lpyl a good bridge therapy for patients with relapsed/refractory diffuse large B-cell lymphoma to potential CAR T-cell therapy.

One year after a 75-year-old patient with diffuse large B-cell lymphoma achieved remission following 6 cycles of R-CHOP, the patient relapsed but declined transplant.

Looking at the challenges with CAR T-cell therapies in patients with diffuse large B-cell lymphoma Justin Kline, MD, discusses the best available therapies for patients who relapse on treatment.

The agent, EZM0414, will be explored in DLBCL, multiple myeloma, and non-multiple myeloma after the completion of a phase 1 dose-finding study.

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old patient with diffuse large B-cell lymphoma presented with fever, drenching night sweats, and recurrent back pain.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Jason Westin, MD, discusses the future of diffuse large B-cell lymphoma treatment.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.